Unknown

Dataset Information

0

Exome analysis of treatment-related AML after APL suggests secondary evolution.

ABSTRACT:

SUBMITTER: Wang T 

PROVIDER: S-EPMC6531372 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Exome-wide association study of treatment-resistant depression suggests novel treatment targets.
| S-EPMC10394052 | biostudies-literature
Unknown Synergistic potential of CDK4/6 inhibitors and ATRA in non-APL AML.
| S-EPMC12512083 | biostudies-literature
Unknown TTMV-RARA fusion as a recurrent cause of AML with APL characteristics.
| S-EPMC9631554 | biostudies-literature
Unknown Progress toward Better Treatment of Therapy-Related AML.
| S-EPMC10046015 | biostudies-literature
Unknown Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC).
| S-EPMC9102836 | biostudies-literature
Unknown AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances.
| S-EPMC7464320 | biostudies-literature
Unknown Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
| S-EPMC6335405 | biostudies-literature
Unknown Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
| S-EPMC6269295 | biostudies-literature
Unknown Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist.
| S-EPMC5962349 | biostudies-literature
Unknown Exome Sequence Analysis Suggests that Genetic Burden Contributes to Phenotypic Variability and Complex Neuropathy.
| S-EPMC4545408 | biostudies-literature